GC Green Cross Signs MOU with Merck for Biopharmaceutical Production Collaboration

Strengthening Cooperation in Supplying Raw and Subsidiary Materials for Biopharmaceutical Production, Including Alglucosidase and Hunterase

Enhancing Manufacturing Process Efficiency and Supply Chain Stability

Operating Regular Technical Consultative Bodies and Exploring Joint R&D Opportunities

GC Green Cross announced on May 14 that it had signed a strategic memorandum of understanding (MOU) with Merck Life Science for cooperation on biopharmaceutical development and GMP manufacturing processes.

From the left, Woong Shin, Head of Operations at GC Green Cross, and Youngim Kim, Head of Process Solutions Business at Merck Life Science, are taking a commemorative photo at the signing ceremony. GC Green Cross

Through this agreement, GC Green Cross plans to strengthen cooperation on the supply of key raw and subsidiary materials required for the production of major biopharmaceuticals, and to establish a collaborative system to improve manufacturing process efficiency and supply chain stability. Merck will provide a comprehensive cooperation framework across all areas of production, from securing raw materials to process technology support. In particular, Merck intends to proactively manage potential supply chain risks in manufacturing processes by reliably supplying product batches that meet strict internal quality control standards.

The two companies plan to operate regular technical and process consultative bodies to strengthen technical cooperation for manufacturing process efficiency. Through this, they aim to share the latest process technology information, enhance quality competitiveness, and continuously seek joint research and development (R&D) opportunities.

Woong Shin, Head of Operations at GC Green Cross, said, "This collaboration will serve as an opportunity to solidify the foundation for the production and supply of major orphan drugs and essential medicines. Through close technical cooperation and process optimization, we will minimize risk throughout manufacturing and establish a production system for pharmaceuticals with world-class quality competitiveness."

Youngim Kim, Head of Process Solutions Business at Merck Life Science, added, "Merck has worked to strengthen customers' production capabilities based on our global technological expertise. Through this collaboration, we will support an optimal production environment to ensure that GC Green Cross's key therapeutics can be supplied stably. Going forward, Merck will continue to contribute to enhancing the competitiveness of the domestic pharmaceutical and biotechnology industry and improving production efficiency."

This content was produced with the assistance of AI translation services.